Eprenetapopt (APR-246), a GSH p53-targeting compound inhibitor, has been shown to be effective in both ARID1A-mutated solid tumors and p53-mutated myelodysplastic syndromes and may be active in ZBTB16-RARA AML (10, 11, 114–116). Here, ZBTB16 is linked to myelodysplastic syndrome.